Orient Europharma (Taiwan) Performance
| 4120 Stock | TWD 50.10 0.30 0.60% |
Orient Europharma has a performance score of 4 on a scale of 0 to 100. The company holds a Beta of -0.38, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Orient Europharma are expected to decrease at a much lower rate. During the bear market, Orient Europharma is likely to outperform the market. Orient Europharma right now holds a risk of 1.96%. Please check Orient Europharma downside deviation, standard deviation, and the relationship between the semi deviation and coefficient of variation , to decide if Orient Europharma will be following its historical price patterns.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Orient Europharma Co are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly abnormal basic indicators, Orient Europharma may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
| Begin Period Cash Flow | 2.1 B | |
| Total Cashflows From Investing Activities | -1.5 B |
Orient |
Orient Europharma Relative Risk vs. Return Landscape
If you would invest 4,725 in Orient Europharma Co on December 17, 2024 and sell it today you would earn a total of 285.00 from holding Orient Europharma Co or generate 6.03% return on investment over 90 days. Orient Europharma Co is generating 0.1241% of daily returns and assumes 1.9627% volatility on return distribution over the 90 days horizon. Simply put, 17% of stocks are less volatile than Orient, and 98% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Orient Europharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Orient Europharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Orient Europharma Co, and traders can use it to determine the average amount a Orient Europharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0632
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | 4120 | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.96 actual daily | 17 83% of assets are more volatile |
Expected Return
| 0.12 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Orient Europharma is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Orient Europharma by adding it to a well-diversified portfolio.
Orient Europharma Fundamentals Growth
Orient Stock prices reflect investors' perceptions of the future prospects and financial health of Orient Europharma, and Orient Europharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Orient Stock performance.
| Return On Equity | -0.0268 | |||
| Return On Asset | -0.0027 | |||
| Profit Margin | (0.02) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 5.9 B | |||
| Shares Outstanding | 86.75 M | |||
| Price To Book | 1.07 X | |||
| Price To Sales | 0.68 X | |||
| Revenue | 4.77 B | |||
| EBITDA | 313.89 M | |||
| Total Debt | 1.68 B | |||
| Book Value Per Share | 33.54 X | |||
| Cash Flow From Operations | 77.65 M | |||
| Earnings Per Share | 0.54 X | |||
| Total Asset | 9.4 B | |||
About Orient Europharma Performance
Evaluating Orient Europharma's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Orient Europharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Orient Europharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Things to note about Orient Europharma performance evaluation
Checking the ongoing alerts about Orient Europharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Orient Europharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| About 65.0% of the company shares are owned by insiders or employees |
- Analyzing Orient Europharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Orient Europharma's stock is overvalued or undervalued compared to its peers.
- Examining Orient Europharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Orient Europharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Orient Europharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Orient Europharma's stock. These opinions can provide insight into Orient Europharma's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Orient Stock Analysis
When running Orient Europharma's price analysis, check to measure Orient Europharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orient Europharma is operating at the current time. Most of Orient Europharma's value examination focuses on studying past and present price action to predict the probability of Orient Europharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Orient Europharma's price. Additionally, you may evaluate how the addition of Orient Europharma to your portfolios can decrease your overall portfolio volatility.